Immune Pharmaceuticals has entered into a contract allowing the firm to reacquire assets for Mylan's Ceplene, or histamine dihydrochloride, a maintenance therapy for acute myeloid leukemia. Immune subsidiary Cytovia would market the drug.
Immune repurchases rights to Mylan's leukemia drug Ceplene
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.